Status: question. Rule: atlas-profile-2.0.
4 linked publications; not a count of independent studies.
Missing appraisal does not mean no evidence exists. Inspect the full profile and source relationships in the interactive Atlas.
Historical grade: WEAK (retained from 22 September 2026; not a completed profile 2.0 assessment).
MGMT governs temozolomide benefit; a false imaging surrogate could misdirect therapy or stratification, yet the task keeps being re-attempted.
Reported AUCs 0.7-0.9 vs rigorous studies finding no reliable MRI-MGMT correlation and attributing success to leakage.
Definitive multi-institutional external test with leakage audit and pre-registered analysis; publish a negative/limits result if warranted.
This question comes from selected literature. Confirm that the gap remains open with a current search and mentor review.
This is an educational research resource from Resonant Labs, not clinical advice. Atlas assessments are heuristic, not probabilities or formal GRADE ratings. Findings are summarized from the literature and may change as the field evolves.